Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
Key opinion leaders navigate barriers to optimal care for patients receiving treatment for PNH.
EP: 1.PNH Overview and Pathophysiology
EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH
Now Viewing
EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH
EP: 5.Complement System Role in PNH Treatment Approach
EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
EP: 7.Efficacy End Points For PNH Treatment
EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors
EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
EP: 10.Investigational Therapies Paving New PNH Treatment Pathways
EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey
EP: 12.Navigating Transfusion Requirements in PNH Treatment
EP: 13.Considerations for Managing PNH Treatment Complications
EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH
EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies
EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
Video content above is prompted by the following:
- What challenges are health care providers commonly faced with regarding the diagnosis and management of paroxysmal nocturnal hemoglobinuria (PNH), given the rarity of the disease and the complexity of its pathophysiology?
- How are electronic health record systems and other health information technology solutions being utilized to aid in the identification of patients with PNH, including those with inadequately controlled disease?
- Please describe the clinical impact and progression of PNH, focusing on the symptoms patients might experience prior to diagnosis, as well as potential complications and comorbidities that may develop over time.
Related Videos
Related Content
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025Article
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
